Demetrian Dornic, MD
Ophthalmology · Cary, NCNPI 1881740090
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Alcon at 28.8% of the total.
Across 112 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$660
- Bausch & Lomb, A Division Of Bausch Health US, LLC$254
- Bausch & Lomb Americas Inc.$194
- Sun Pharmaceutical Industries Inc.$175
- Glaukos Corporation$169
- AbbVie$130
- plus $708 from 15 others
Across 6 payments — averaging $4786.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$29K
What the payments were for
- Food & beverage$2,289100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 33 | $660 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 19 | $254 |
| Bausch & Lomb Americas Inc. | 9 | $194 |
| Sun Pharmaceutical Industries Inc. | 8 | $175 |
| Glaukos Corporation | 2 | $169 |
| AbbVie(2 entities) | 6 | $130 |
| Oyster Point Pharma, Inc. | 6 | $128 |
| Eyevance Pharmaceuticals LLC | 6 | $120 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $89 |
| Harrow Eye, LLC | 2 | $70 |
| Novartis | 3 | $56 |
| Biotissue Holdings Inc. | 3 | $49 |
| Kala Pharmaceuticals, Inc. | 2 | $38 |
| Tarsus Pharmaceuticals, Inc. | 1 | $26 |
| Rxsight Inc | 1 | $25 |
| Aerie Pharmaceuticals, Inc. | 2 | $22 |
| Shire North American Group Inc | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $17 |
| Sight Sciences, Inc. | 1 | $17 |
| Ivantis, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent inject W$137
- KXL System$137
- Photrexa$137
How this compares
$2,289 in reported general payments places this provider in the 60th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 129 | $149,218 |
| Prednisolone Acetate | 1,468 | $69,844 |
| LumiganBimatoprost | 120 | $58,857 |
| MoxifloxacinMoxifloxacin Hcl | 1,341 | $30,387 |
| Ketorolac Tromethamine | 1,225 | $23,085 |
| XiidraLifitegrast | 13 | $19,606 |
| RocklatanNetarsudil Mesylat/Latanoprost | 46 | $18,888 |
| TyrvayaVarenicline Tartrate | 25 | $16,008 |
| CombiganBrimonidine Tartrate/Timolol | 38 | $15,812 |
| Latanoprost | 1,028 | $11,553 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 53 | $11,143 |
| Cyclosporine | 16 | $10,324 |
| Timolol Maleate | 547 | $8,430 |
| Fluorometholone | 93 | $7,348 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $4,119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $130 | $223,887287 claims |
| Bausch & Lomb Americas Inc.Xiidra | $194 | $19,60613 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $22 | $18,88846 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $128 | $16,00825 claims |
| AlconSimbrinza | $660 | $11,14353 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $254 | $3,18622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Cary
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
- Karl StonecipherGreensboro$653K
- Terry KimDurham$605K
- Keith WalterWinston Salem$397K
- Leon HerndonDurham$230K
- Thomas MundorfCharlotte$220K
- Glenn JaffeDurham$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.